Searched for
VEEDA CLINICAL RESEARCH
Blockbuster November looms for India’s IPO market with over Rs 76,000 crore worth of issues lined upIndia's IPO market anticipates a blockbuster November, with over ₹76,000 crore in public issues expected across various sectors. This surge...- IPO Calendar: Primary market regains momentum with 3 new issues opening next weekIndia’s IPO market revives this week with three new issues worth over Rs 1,750 crore — Orkla India, Game Changers Texfab, and Jayesh Logist...
- Pharma, healthcare firms eye Rs 13,000-cr IPO wave over 9 monthsIndian pharmaceutical and healthcare firms are set for a significant fundraising push, aiming to garner ₹12,000-13,000 crore through IPOs i...
- School Assembly Headlines for July 9: Top national, international, sports, business news hereIndia is set to reshape BRICS in 2026, while a nationwide strike involving millions of workers and farmers is expected. Internationally, Tr...
- Sebi clears IPO proposals of 5 companies; WeWork India’s public offer taken out of abeyanceSebi has approved IPO plans for Veeda Clinical, Shringar Mangalsutra, RITE Water, Seedworks, and LCC Projects, boosting India's primary mar...
- Dr Agarwal's Health Care shares list flat at Rs 397 on BSEDr Agarwal's Health Care shares debuted with a 1.2% discount on the BSE and slightly higher on the NSE. The largest eye care chain in India...
- Veeda Clinical Research refiles DRHP for IPO with SebiVeeda Clinical Research: Veeda Clinical Research has refiled its IPO papers with SEBI, planning to raise funds through a fresh issue and of...
- Veeda Clinical Research refiles DRHP with SEBICX Partners backed Veeda Clinical Research, a full-service contract research organization (CRO) has refiled its Draft Red Herring Prospectu...
- Veeda Clinical Research names Mahesh Bhalgat as group CEOMahesh Bhalgat has been appointed as the Group CEO of Veeda Clinical Research, an Ahmedabad-based clinical research organization. Bhalgat h...
- Ex-Blackstone India co-head Mathew Cyriac’s fund buys 80% stake in Accutest Research LaboratoriesIn the next five years, drug patents with sales worth $170 billion will expire globally, driving demand for cost-effective generic drugs. A...
- More healthcare businesses keen to take a shot at primary marketDespite being people-centric, the workings of the Indian healthcare industry are not largely known to the public. The Indian healthcare eco...
- It's IPOs ahoy! 40-odd issues on the way to mop up Rs 80,000 croreIn 2020, 16 issues had mopped up Rs 26,628 crore, and a similar number of IPOs had collected Rs 12,687 crore in 2019, but 2018 was the best...
- Delay in approvals unacceptable: Gujarat CROsAny delay in approvals will be a violation of "Right to Life guaranteed by the Constitution" says Gujarat's CROs.
- After SC rap, govt set to notify rules to regulate drug trialsAsking for the personal presence of Health Secretary in the matter, the SC gave the Ministry four weeks to respond to a PIL.
- Fresenius Kabi to pay higher compensation to clinical trial victimsFresenius Kabi Oncology, the Indian arm of Germany's Fresenius Kabi will increase the compensation it paid to families of two volunteers wh...
- Lack of compensation norms for clinical trials results in exploitation of poor patientsDrug companies paid as little as 50,000 as compensation to families of volunteers who died during clinical trials for new medicines last ye...
- Pharma cos may trim clinical research spend as budget shrinksThe clinical research business in India, which has growing at a robust pace over the past few years, is likely to face a slowdown in 2009-1...
- Veeda Oncology acquires Biologie et IndustrieVeeda Oncology on Tuesday said it has completed the acquisition of Paris-based Biologie et Industrie bolstering its presence in the segment.
- Small cos make big splash in global M&A marketsAs the sharks go hunting in overseas waters, the small fish too are on the same prowl.
- India, Inc.'s small fishes get bigSmall firms are increasingly breaking the home shell and making significant acquisitions globally.
Load More
